• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

艾拉莫德治疗类风湿关节炎的疗效和安全性。

Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis.

作者信息

Li Jiangtao, Mao Hejuan, Liang Yan, Lu Yanrong, Chen Shuo, Yang Nanping, Shi Guixiu

机构信息

West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China ; Department of Rheumatology and Immunology, The First People's Hospital of Yibin, Yibin, Sichuan 644000, China.

Department of Otolaryngology, The First People's Hospital of Yibin, Yibin, Sichuan 644000, China.

出版信息

Clin Dev Immunol. 2013;2013:310628. doi: 10.1155/2013/310628. Epub 2013 Nov 26.

DOI:10.1155/2013/310628
PMID:24371446
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3858866/
Abstract

All randomized controlled trials (RCTs) of iguratimod for rheumatoid arthritis (RA) to assess its efficacy and safety are included in this paper. The Review Manager software was used for meta-analysis to assess risk bias of the studies included, and GRADE profiler software was used for the evidence quality of the studies included. Four RCTs involving 1407 patients with RA were included. Meta-analyses showed that, after 24-week therapy, ACR20, tender joint count, swollen joint count, rest pain, physician and patient global assessment of disease activity, HAQ score, ESR, and CRP in iguratimod group were better than those in placebo group and that the difference between those of iguratimod group and those of other DMARDs (MTX and SASP) group was not significant. GRADE evidence classification of the studies included was moderate. Iguratimod for RA had few adverse events, and its efficacy and safety were the same as those of MTX and SASP for RA. The results of this systematic review suggest that more high-quality and large-scaled RCTs were needed to determine the efficacy of iguratimod for RA and whether iguratimod is as effective as other DMARDs besides MTX and SASP.

摘要

本文纳入了所有评估艾拉莫德治疗类风湿关节炎（RA）疗效和安全性的随机对照试验（RCT）。采用Review Manager软件进行荟萃分析，以评估纳入研究的风险偏倚，并使用GRADEprofiler软件评估纳入研究的证据质量。纳入了4项涉及1407例RA患者的RCT。荟萃分析表明，治疗24周后，艾拉莫德组的美国风湿病学会20%改善标准（ACR20）、压痛关节数、肿胀关节数、静息痛、医生和患者对疾病活动的整体评估、健康评估问卷（HAQ）评分、红细胞沉降率（ESR）和C反应蛋白（CRP）均优于安慰剂组，且艾拉莫德组与其他改善病情抗风湿药（MTX和柳氮磺胺吡啶[SASP]）组之间的差异无统计学意义。纳入研究的GRADE证据分级为中等。艾拉莫德治疗RA的不良事件较少，其疗效和安全性与MTX和SASP治疗RA的疗效和安全性相当。该系统评价结果提示，需要更多高质量、大规模的RCT来确定艾拉莫德治疗RA的疗效，以及艾拉莫德是否与MTX和SASP以外的其他改善病情抗风湿药疗效相当。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/009025fe4aac/CDI2013-310628.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/f07db7d9178e/CDI2013-310628.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/aadd5307435c/CDI2013-310628.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/3ca7003be5cf/CDI2013-310628.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/35c80dd979c2/CDI2013-310628.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/d06e81cd0958/CDI2013-310628.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/0ed07230fe4c/CDI2013-310628.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/b204a5d99e61/CDI2013-310628.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/b58f4a7fbc18/CDI2013-310628.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/34ceba5ece71/CDI2013-310628.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/b99aa802477e/CDI2013-310628.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/cbe8c92c22fe/CDI2013-310628.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/44750e28ef39/CDI2013-310628.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/009025fe4aac/CDI2013-310628.013.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/f07db7d9178e/CDI2013-310628.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/aadd5307435c/CDI2013-310628.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/3ca7003be5cf/CDI2013-310628.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/35c80dd979c2/CDI2013-310628.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/d06e81cd0958/CDI2013-310628.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/0ed07230fe4c/CDI2013-310628.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/b204a5d99e61/CDI2013-310628.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/b58f4a7fbc18/CDI2013-310628.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/34ceba5ece71/CDI2013-310628.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/b99aa802477e/CDI2013-310628.010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/cbe8c92c22fe/CDI2013-310628.011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/44750e28ef39/CDI2013-310628.012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fb6e/3858866/009025fe4aac/CDI2013-310628.013.jpg

相似文献

1
Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis.艾拉莫德治疗类风湿关节炎的疗效和安全性。
Clin Dev Immunol. 2013;2013:310628. doi: 10.1155/2013/310628. Epub 2013 Nov 26.
2
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
3
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).生物制剂或托法替布单药治疗传统抗风湿药物（DMARD）治疗失败的类风湿关节炎患者：一项Cochrane系统评价和网状Meta分析（NMA）
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD012437. doi: 10.1002/14651858.CD012437.
4
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
5
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
6
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
7
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病：网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗：一项网状Meta分析。
Cochrane Database Syst Rev. 2020 Jan 9;1(1):CD011535. doi: 10.1002/14651858.CD011535.pub3.
10
Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis.叶酸和亚叶酸用于减轻类风湿关节炎患者接受甲氨蝶呤治疗时的副作用。
Cochrane Database Syst Rev. 2013 May 31;2013(5):CD000951. doi: 10.1002/14651858.CD000951.pub2.

引用本文的文献

1
Pharmacological pain management in patients with rheumatoid arthritis: a narrative literature review.类风湿关节炎患者的药物性疼痛管理：一篇叙述性文献综述
BMC Med. 2025 Jan 29;23(1):54. doi: 10.1186/s12916-025-03870-0.
2
Signaling pathways in rheumatoid arthritis: implications for targeted therapy.类风湿关节炎中的信号通路：靶向治疗的意义。
Signal Transduct Target Ther. 2023 Feb 17;8(1):68. doi: 10.1038/s41392-023-01331-9.
3
2018 Chinese Guidelines for the Diagnosis and Treatment of Rheumatoid Arthritis.《2018年中国类风湿关节炎诊疗指南》

本文引用的文献

1
Concomitant iguratimod therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate: a randomized, double-blind, placebo-controlled trial.在甲氨蝶呤稳定剂量治疗下仍处于活动期的类风湿关节炎患者中联合使用来氟米特治疗：一项随机、双盲、安慰剂对照试验。
Mod Rheumatol. 2013 May;23(3):430-9. doi: 10.1007/s10165-012-0724-8. Epub 2012 Jul 26.
2
T-614 alters the production of matrix metalloproteinases (MMP-1 andMMP-3) and inhibits the migratory expansion of rheumatoid synovial fibroblasts, in vitro.T-614 改变基质金属蛋白酶（MMP-1 和 MMP-3）的产生，并抑制体外类风湿性滑膜成纤维细胞的迁移和扩张。
Int Immunopharmacol. 2012 May;13(1):54-60. doi: 10.1016/j.intimp.2012.03.003. Epub 2012 Mar 21.
3
Rheumatol Immunol Res. 2021 Apr 13;2(1):1-14. doi: 10.2478/rir-2021-0002. eCollection 2021 Mar.
4
Effectiveness and Safety of Iguratimod Monotherapy or Combined With Methotrexate in Treating Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.艾拉莫德单药治疗或联合甲氨蝶呤治疗类风湿关节炎的有效性和安全性：一项系统评价和荟萃分析。
Front Pharmacol. 2022 Aug 5;13:911810. doi: 10.3389/fphar.2022.911810. eCollection 2022.
5
A Systematic Review and Meta-Analysis of 19 Randomized Controlled Trials of Iguratimod Combined With Other Therapies for Sjogren's Syndrome.一项系统性综述和荟萃分析，共纳入 19 项随机对照试验，评估了伊古曲替姆联合其他疗法治疗干燥综合征的疗效。
Front Immunol. 2022 Jul 28;13:924730. doi: 10.3389/fimmu.2022.924730. eCollection 2022.
6
Effectiveness and safety of iguratimod treatment in patients with active rheumatoid arthritis in Chinese: A nationwide, prospective real-world study.艾拉莫德治疗中国活动性类风湿关节炎患者的有效性和安全性：一项全国性、前瞻性真实世界研究。
Lancet Reg Health West Pac. 2021 Mar 22;10:100128. doi: 10.1016/j.lanwpc.2021.100128. eCollection 2021 May.
7
Iguratimod promotes transformation of mononuclear macrophages in elderly patients with rheumatoid arthritis by nuclear factor-κB pathway.艾拉莫德通过核因子κB途径促进老年类风湿关节炎患者单核巨噬细胞的转化。
World J Clin Cases. 2021 Apr 6;9(10):2181-2191. doi: 10.12998/wjcc.v9.i10.2181.
8
In Situ Forming Injectable Hydrogel For Encapsulation Of Nanoiguratimod And Sustained Release Of Therapeutics.原位形成可注射水凝胶用于封装奈诺沙星和治疗药物的持续释放。
Int J Nanomedicine. 2019 Nov 6;14:8725-8738. doi: 10.2147/IJN.S214507. eCollection 2019.
9
Iguratimod: a valuable remedy from the Asia Pacific region for ameliorating autoimmune diseases and protecting bone physiology.艾拉莫德：一种来自亚太地区的用于改善自身免疫性疾病和保护骨骼生理功能的珍贵药物。
Bone Res. 2019 Sep 3;7:27. doi: 10.1038/s41413-019-0067-6. eCollection 2019.
10
Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis.艾拉莫德对类风湿关节炎患者Th亚群平衡及炎性细胞因子的调控作用
Mediators Inflamm. 2015;2015:356040. doi: 10.1155/2015/356040. Epub 2015 Dec 2.
Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate.
T-614与甲氨蝶呤治疗活动性类风湿关节炎的多中心、随机、双盲、对照试验
Arthritis Rheum. 2009 Jul 15;61(7):979-87. doi: 10.1002/art.24643.
4
T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis.新型免疫调节剂T-614可减轻胶原诱导性关节炎中的关节炎症和关节损伤。
Arthritis Res Ther. 2008;10(6):R136. doi: 10.1186/ar2554. Epub 2008 Nov 19.
5
Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.T-614治疗活动性类风湿关节炎患者的安全性和有效性：一项双盲、随机、安慰剂对照的多中心试验。
Chin Med J (Engl). 2008 Apr 5;121(7):615-9.
6
Long-term safety study of iguratimod in patients with rheumatoid arthritis.艾拉莫德治疗类风湿关节炎患者的长期安全性研究。
Mod Rheumatol. 2007;17(1):10-6. doi: 10.1007/s10165-006-0543-x. Epub 2007 Feb 20.
7
Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study.艾拉莫德与安慰剂及柳氮磺胺吡啶治疗活动性类风湿关节炎的疗效和安全性比较：一项对照、多中心、双盲、平行组研究
Mod Rheumatol. 2007;17(1):1-9. doi: 10.1007/s10165-006-0542-y. Epub 2007 Feb 20.
8
Inhibitory effects of an anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice.抗风湿药物T-614对培养的B细胞及移植到SCID小鼠体内的类风湿滑膜组织产生免疫球蛋白的抑制作用。
Rheumatology (Oxford). 2003 Nov;42(11):1365-71. doi: 10.1093/rheumatology/keg381. Epub 2003 Jun 16.
9
Inhibitory effect of T-614 on tumor necrosis factor-alpha induced cytokine production and nuclear factor-kappaB activation in cultured human synovial cells.T-614对培养的人滑膜细胞中肿瘤坏死因子-α诱导的细胞因子产生及核因子-κB激活的抑制作用
J Rheumatol. 2001 Dec;28(12):2591-6.
10
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria.欧洲抗风湿病联盟类风湿关节炎反应标准的制定与验证。与美国风湿病学会初步标准及世界卫生组织/国际抗风湿病联盟标准的比较。
Arthritis Rheum. 1996 Jan;39(1):34-40. doi: 10.1002/art.1780390105.